Curcumin inhibits the AKT/NF-κB signaling via CpG demethylation of the promoter and restoration of NEP in the N2a cell line

AAPS Journal

Volumn 16, Issue 4, 2014, Pages 649-657

  Deng, Yushuang ^a   Lu, Xi ^a   Wang, Li ^b   Li, Tao ^c   Ding, Yubin ^a   Cao, Huimin ^a   Zhang, Yuping ^a   Guo, Xiuming ^a   Yu, Gang ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Chongqing Cancer Institute   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

AKT NF B signaling; Alzheimer's disease; Curcumin; DNA methylation; Neprilysin

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CURCUMIN; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MEMBRANE METALLOENDOPEPTIDASE; PROTEIN KINASE B; AMYLOID PRECURSOR PROTEIN; ONCOPROTEIN;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION; MOUSE; NEPRILYSIN GENE; NONHUMAN; PROMOTER REGION; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HUMAN; METABOLISM; TUMOR CELL LINE;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELL LINE, TUMOR; CPG ISLANDS; CURCUMIN; DNA METHYLATION; GENE EXPRESSION; HUMANS; MICE; NEPRILYSIN; NF-KAPPA B; ONCOGENE PROTEIN V-AKT; SIGNAL TRANSDUCTION;

EID: 84903608479     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9605-8     Document Type: Article

References (47)

1. Abbott A. Dementia: a problem for our age. Nature. 2011;475:S2-4. doi:10.1038/475S2a.
2. Selkoe DJ. Inflammation and therapeutic vaccination in CNS diseases. Nature. 2002;420:879-84. doi:10.1038/nature01325. (Pubitemid 36019642)
3. Revesz T. Inflammation in Alzheimer's disease: insights from immunotherapy. Brain. 2013;136:2654-6. doi:10.1093/brain/awt231.
4. Manning BD. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261-74. doi:10.1016/j.cell.2007.06.009. (Pubitemid 46962095)
5. Delhase M, Li N, Karin M. Kinase regulation in inflammatory response. Nature. 2000;406:367-8. doi:10.1038/35019154.
6. Robertson M. Alzheimer's disease and amyloid. Nature. 1992;356:103. doi:10.1038/356103a0.
7. Ferrer I, Martí E, López E, Tortosa A. NF-κB immunoreactivity is observed in association with beta A4 diffuse plaques in patients with Alzheimer's disease. Neuropathol Appl Neurobiol. 1998;24:271-7. doi:10.1046/j.1365-2990.1998.00116.x. (Pubitemid 28389123)
8. Gonzalo MR, Martin B, Sanz-Anquela JM, Arevalo-Serrano J, Gonzalo-Ruiz A. Oligomers of beta-amyloid protein (Abeta1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interactionwith interleukin-1beta, tumour necrosis factor-alpha, and a nuclear factor kappa-B mechanism in the rat brain. Exp Neurol. 2012;236:215-27. doi:10.1016/j.expneurol.2012.05.004.
9. Hama E, Shirotani K, Iwata N, Saido TC. Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid beta peptide clearance in primary neurons. J Biol Chem. 2004;279:30259-64. doi:10.1074/jbc.M401891200. (Pubitemid 38937952)
10. Marr RA, Guan H, Rockenstein E, Kindy M, Gage FH, Verma I, et al. Neprilysin regulates amyloid beta peptide levels. J Mol Neurosci. 2004;22:5-11. doi:10.1385/JMN:22:1-2:5. (Pubitemid 41359010)
11. Dai J, Mikhail M, Navarro D, Taneja SS, Lee P, Christos P, et al. Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer. 2006;107:2628-36. doi:10.1002/cncr. 22312. (Pubitemid 44845618)
12. Ando H, Nagasaka T, Shibata D, Harata T, Shimomura Y, Goto M, et al . Neutral endopeptidase expressed by decidualized stromal cells suppresses akt phosphorylation and deoxyribonucleic acid synthesis induced by endothelin-1 in human endometrium. Endocrinology. 2006;147:5153-9. doi:10.1210/en.2006-0172. (Pubitemid 44790569)
13. Russo R, Borghi R, Markesbery W, Tabaton M, Piccini A. Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. FEBS Lett. 2005;579:6027-30. doi:10.1016/j.febslet.2005.09.054. (Pubitemid 41546241)
14. Martin C, Zhang Y. Mechanisms of epigenetic inheritance. Curr Opin Cell Biol. 2007;19:266-72. doi:10.1016/j.ceb.2007.04.002. (Pubitemid 46899505)
15. Chen KL, Wang SS, Yang YY, Yuan RY, Chen RM, Hu CJ. The epigenetic effects of amyloid-beta (1-40) on global DNA and neprilysin genes in murine cerebral endothelial cells. Biochem Biophys Res Commun. 2009;378:57-61. doi:10.1016/j.bbrc.2008.10.173.
16. Takahashi M, Yoshida M, Igarashi M, Nakae D. Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma. Cancer Sci. 2006;97:611-7. (Pubitemid 44056609)
17. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30:85-94. doi:10.1016/j.tips.2008.11.002.
18. Shehzad A, Rehman G, Lee YS. Curcumin in inflammatory diseases. Biofactors. 2013;39:69-77. doi:10.1002/biof.1066.
19. Thangapazham RL, Sharma A, Maheshwari RK. Multiplemolecular targets in cancer chemoprevention by curcumin. AAPS J. 2006;8:E443-9. doi:10.1208/ aapsj080352. (Pubitemid 44096605)
20. Nagaraju GP, Aliya S, Zafar SF, Basha R, Diaz R, El-Rayes BF. The impact of curcumin on breast cancer. Integr Biol (Camb). 2012;4:996-1007. doi:10.1039/c2ib20088k.
21. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65:1631-52. doi:10.1007/s00018-008-7452-4.
22. Dhillon N, Aggarwal BB, Newman RA,Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14:4491-9. doi:10.1158/1078-0432.
23. Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer. 2010;116:4670-6. doi:10.1002/cncr.25414.
24. Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S, Yu J, et al. Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett. 2009;19:706-9. doi:10.1016/j.bmcl.2008.12.041.
25. Nagaraju GP, Zhu S, Wen J, Farris AB, Adsay VN, Diaz R, et al. Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Lett. 2013;341:195-203. doi:10.1016/j. canlet.2013.08.002.
26. Nagaraju GP, Zhu S, Ko JE, Shoji M, El-Rayes B. Antiangiogenic effects of curcumin and its novel analogs EF-31 and UBS-109 in colorectal cancer. FASEB J. 2013;27(Meeting Abstract Supplement):lb574.
27. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754-60. doi:10.1038/375754a0.
28. Kim HS, Lim JY, Sul D, Hwang BY, Won TJ, Hwang KW, et al. Neuroprotective effects of the new diterpene, CBNU06 against beta-amyloid-induced toxicity through the inhibition of NFkappaB signaling pathway in PC12 cells. Eur J Pharmacol. 2009;622:25-31. doi:10.1016/j.ejphar.2009.09.007.
29. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst. 2005;97:1498-506. doi:10.1093/jnci/dji311. (Pubitemid 41631949)
30. Wang ZF, Li HL, Li XC, Zhang Q, Tian Q,Wang Q, et al. Effects of endogenous β-amyloid overproduction on tau phosphorylation in cell culture. J Neurochem. 2006;98:1167-75. doi:10.1111/j.1471-4159.2006.03956.x. (Pubitemid 44127792)
31. Ding GJ, Fischer PA, Boltz RC, Schmidt JA, Colaianne JJ, Gough A, et al. Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin-1 and tumor necrosis factor-alpha. Development and use of a high capacity fluorescence cytometric system. J Biol Chem. 1998;273:28897-905. doi:10.1074/jbc.273.44.28897. (Pubitemid 28507582)
32. Adwan L, Zawia NH. Epigenetics: a novel therapeutic approach for the treatment of Alzheimer 's disease. Pharmacol Ther. 2013;139:41-50. doi:10.1016/j.pharmthera.2013.03.010.
33. Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2006;65:1012-21. doi:10.1097/01.jnen.0000240463.87886.9a. (Pubitemid 44521802)
34. Lentzen H, Monden I, Linke J, Palenker J. No evidence for enkephalinase A on neuronal cells. Life Sci. 1983;33:105-8. doi:10.1016/0024-3205(83)90455-1. (Pubitemid 14249940)
35. Hong Y, Beckett C, Belyaev ND, Turner AJ. The impact of amyloid precursor protein signalling and histone deacetylase inhibition on neprilysin expression in human prostate cells. Int J Cancer. 2012;130:775-86. doi:10.1002/ijc.26028.
36. Belyaev ND, Nalivaeva NN, Makova NZ, Turner AJ. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep. 2009;10:94-100. doi:10.1038/embor.2008.222.
37. Wright J. Epigenetics: reversible tags. Nature. 2013;498:S10-1. doi:10.1038/498S10a.
38. Link A, Balaguer F, Shen Y, Lozano JJ, Leung HC, Boland CR, et al. Curcumin modulates DNA methylation in colorectal cancer cells. PLoS ONE. 2013;8:e57709. doi:10.1371/journal.pone.0057709.
39. Khor TO, Huang Y, Wu TY, Shu L, Lee J, Kong AN. Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs emethylation. Biochem Pharmacol. 2011;82:1073-8. doi:10.1016/j.bcp.2011.07.065.
40. Shu L, Khor TO, Lee JH, Boyanapalli SS, Huang Y, Wu TY, et al. Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells. AAPS J. 2011;13:606-14. doi:10.1208/s12248-011-9300-y.
41. Liu YL, Yang HP, Gong L, Tang CL, Wang HJ. Hypomethylation effects of curcumin, demethoxycurcumin and bisdemethoxycurcumin on WIF-1 promoter in non-small cell lung cancer cell lines. Mol Med Rep. 2011;4:675-9. doi:10.3892/mmr.2011.473.
42. Yu J, Peng Y, Wu LC, Xie Z, Deng Y, Hughes T, et al. Curcumin down-regulates DNA methyltransferase 1 and plays an antileukemic role in acute myeloid leukemia. PLoS ONE. 2013;8:e55934. doi:10.1371/journal.pone.0055934.
43. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184-5. doi:10.1126/science.1566067.
44. Shakibaei M, John T, Schulze TG, Lehmann I, Mobasheri A. Suppression of NF-κB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem Pharmacol. 2007;73:1434-45. doi:10.1016/j.bcp.2007.01.005. (Pubitemid 46452591)
45. Moriyuki K, Sekiguchi F, Matsubara K, Nishikawa H, Kawabata A. Curcumin inhibits the proteinase-activated receptor-2-triggered prostaglandin E2 production by suppressing cyclooxygenase-2 upregulation and Akt-dependent activation of nuclear factor-κ B in human lung epithelial cells. J Pharmacol Sci. 2010;114:225-9. doi:10.1254/jphs.10126SC.
46. Mosca M, Lucciarini R, Perfumi MC, Santoni G. Thiorphaninduced survival and proliferation of rat thymocytes by activation of Akt/survivin pathway and inhibition of caspase-3 activity. J Pharmacol Exp Ther. 2008;327:215-25. doi:10.1124/jpet.108.138719.
47. Li W, Wu Y, Min F, Li Z, Huang J, Huang R. A nonhuman primate model of Alzheimer's disease generated by intracranial injection of amyloid-beta42 and thiorphan. Metab Brain Dis. 2010;25:277-84. doi:10.1007/s11011-010-9207-9.